Innovation of cancer therapy has received a dramatic acceleration over the last fifteen years
thanks to the introduction of the novel immune checkpoint inhibitors (ICI). On the other hand …

Cancer immunotherapy, as an emerging approach to cancer treatment, has tremendous
potential for application. Compared to traditional methods such as surgery, chemothera-py …

Enzyme catalytic activities are critical biomarkers of tissue states under physiological and
pathophysiological conditions. However, the direct measurement and imaging of enzyme …

While A2A adenosine receptor (AR) was considered as a major contributor to adenosine-
mediated immunosuppression, A2B, having the lowest affinity to adenosine, has also …

Inflammatory skin diseases highlight inflammation as a central driver of skin pathologies,
involving a multiplicity of mediators and cell types, including immune and non-immune cells …

Cancer, a complex array of diseases, involves the unbridled proliferation and dissemination
of aberrant cells in the body, forming tumors that can infiltrate neighboring tissues and …

The adenosine subfamily G protein-coupled receptors A2AR and A2BR have been identified
as promising cancer immunotherapy candidates. One of the A2AR/A2BR dual antagonists …

Simple Summary Lung cancer remains the most important cause of cancer-related mortality
worldwide. Immune checkpoint inhibitors revolutionized lung cancer care. These molecules …

Fluorescent ligands have proved to be powerful tools in the study of G protein‐coupled
receptors in living cells. Here we have characterized a new fluorescent ligand PSB603 …

The A 2B adenosine receptor (A 2B R) is one of the four adenosine-activated G protein-
coupled receptors. In addition to adenosine, protein kinase C (PKC) was recently found to …